Neuroendocrine tumours: open trials in Mexico

• NCT06943755

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  Trial Treatment · Phase 2/3 · Exelixis

  Instituto Nacional de Cancerologia, Mexico City

  Registry updated 2026-10-30

• NCT07544654

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Trial Treatment · Phase 3 · Boehringer Ingelheim

  Centro Medico Nacional de Occidente/ Centro De Investigacion Biomedica De Occidente, Guadalajara, Jalisco · Centro Oncologico Personalizado, México · Health Pharma Professional Research S.A. de C.V., Mexico City · Centro Oncologico Estatal ISSEMYM, Toluca · Instituto Jaliciense de Cancerología, Zapopan

  Registry updated 2026-10-28

• NCT07192991

  Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

  Research · Latin American Cooperative Oncology Group

  Centro Oncológico Internacional (COI), Mexico City · INCan - Instituto Nacional de Cancerología, Mexico City

  Registry updated 2026-09-08

• NCT05040360

  Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

  Trial Treatment · Phase 2 · SWOG Cancer Research Network

  Instituto Nacional De Cancerologia de Mexico, Mexico City

  Registry updated 2025-12-15

• NCT06523582

  Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

  Research · Universidad Nacional Autonoma de Mexico

  Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City · Red de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico City · Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City

  Registry updated 2024-07-26

All Neuroendocrine tumours trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error